Determining Resistance to a Taxane or Anthracyclines in Breast Cancer
Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she determines if a patient is resistant to a taxane or anthracyclines.
Treating a Patient With HER2-Negative Metastatic Breast Cancer
Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she would treat a patient with HER2-negative metastatic breast cancer.